Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intranasal oxytocin versus placebo during fMRI threat processing in generalized social anxiety disorder
ACTRN12607000141448Phase 3Completed
- Sponsor
- Monash University
- Start
- Mar 2008
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of oxytocin in Social Anxiety Disorder (SAD) (2 arms), sponsored by Monash University. Primary endpoint: Amygdala response to threatening versus non-threatening facial expressions. Started Mar 2008; status: completed.
02
Drugs
oxytocin
03
Conditions
Social Anxiety Disorder (SAD)
Beyond the preview
Go deeper on ACTRN12607000141448.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12607000141448.